We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ABIO ARCA Biopharma Inc

-0.0132 (-0.72%)
Last Updated: 12:34:23
Delayed by 15 minutes


Draw Mode:

Volume 13,384
Bid Price 1.80
Ask Price 1.81
News -
Day High 1.82


52 Week Range


Day Low 1.80
Share Name Share Symbol Market Stock Type
ARCA Biopharma Inc ABIO NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.0132 -0.72% 1.81 12:34:23
Open Price Low Price High Price Close Price Previous Close
1.80 1.80 1.82 1.8232
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
137 13,384 US$ 1.81 US$ 24,226 - 1.7351 - 2.6999
Last Trade Type Quantity Price Currency
14:35:55 5 US$ 1.81 USD

ARCA Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
26.08M 14.41M - 0 -9.93M -0.69 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

ARCA Biopharma News

Date Time Source News Article
12/05/202315:25Edgar (US Regulatory)Form 8-K - Current report
12/04/202315:36Edgar (US Regulatory)Form 8-K - Current report
10/18/202315:35Edgar (US Regulatory)Form 8-K - Current report
10/18/202315:25GlobeNewswire Inc.ARCA biopharma Announces Third Quarter 2023 Financial..
10/18/202315:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
9/11/202315:01Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial..
7/21/202315:35Edgar (US Regulatory)Form 8-K - Current report
7/21/202315:25GlobeNewswire Inc.ARCA biopharma Announces Second Quarter 2023 Financial..
7/21/202315:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]
4/24/202315:25GlobeNewswire Inc.ARCA biopharma Announces First Quarter 2023 Financial..
2/24/202315:20GlobeNewswire Inc.ARCA biopharma Announces 2022 Financial Results and Provides..
12/19/202215:05GlobeNewswire Inc.James Flynn Joins ARCA biopharma Board of Directors
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ABIO Message Board. Create One! See More Posts on ABIO Message Board See More Message Board Posts

Historical ABIO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.831.881.781.8316,587-0.02-1.09%
1 Month1.831.951.73591.8416,261-0.02-1.09%
3 Months2.062.07271.73511.9421,675-0.25-12.14%
6 Months2.102.161.73512.0022,351-0.29-13.81%
1 Year2.162.69991.73512.1327,306-0.35-16.2%
3 Years4.095.501.713.59216,294-2.28-55.75%
5 Years0.5122.000.26257.13379,7121.30254.9%

ARCA Biopharma Description

ARCA biopharma Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to the development and commercialization of targeted therapies for cardiovascular diseases. The company's product candidates are rNAPc2 as a potential treatment for COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and potentially other viral diseases and Gencaro for the treatment of atrial fibrillation, or AF, in patients with chronic heart failure, or HF. rNAPc2 targets COVID-19 patients with biomarker evidence of coagulopathy, while Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |